The European Pharmacopeia needs to remain relevant and aligned with the latest changes in the pharmaceutical sector. In this edition, nearly one third of the content is new or revised. It is an essential tool for national competent authorities and manufacturers as it defines binding quality requirements for medicines.
New monographs on active substances and finished products covering key therapeutic classes: from anti-thrombotic to immunosuppressants, including a series of new general chapters. Much was also accomplished in the field of biologicals.
A network of 700 experts sitting on more than 61 expert groups and working parties. These experts come from all over the world and represent all relevant disciplines in pharmaceutical sciences.
The European Pharmacopeia Commission is committed to reviewing and reducing the use of animals in quality control tests of medicines. Its work is based on the European Convention for the Protection of Vertebrate Animals used for Experimental and Other Scientific Purposes, which is designed to reduce both the number of experiments and the number of animals used for such purposes.